Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by collinscon Jan 14, 2008 4:41pm
249 Views
Post# 14201140

RE: News?

RE: News?"McCaffrey noted, 'Due to the successful early trending of our Phase 1 program we have decided that upon official completion of the trial, FDA discussions and approval, we will be expediting our plans for a Phase 2 trial." Huh? No pending sale? "This could shorten the time to reach our Phase 2 trial by several months. In addition, follow on studies in cardiovascular disease patients are being discussed with potential collaborators. " Huh?I'm really confused now will all that talk about a "SALE' soon being changed to"This should shorten the time to reach OUR PHASE 2 TRIAL BY SEVERAL MONTHS". Would someone like to explain the difference between a 'buyer' and a 'collaborator'? I know my definition but what's yours? Oh, yes, I like that word 'Potential' too. I have the potential of having a heart attack but that doen't mean that I will have a heart attack. Did someone say a possible sale early in the year? Now what year might that be? I'm not knocking this stock. I'm just trying to compare the news with all I've been reading from those who seem to have their "contacts"[LOL].
Bullboard Posts